Home › Funds › Palo Alto Investors LP › ORKA
Palo Alto Investors LP position in ORKA
ORUKA THERAPEUTICS INC · Health Care
Palo Alto Investors LP reported holding 25,563 shares of ORKA (ORUKA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$2.1M, representing 0.32% of its reported portfolio and ranking #38 among its reported holdings. Palo Alto Investors LP has disclosed ORKA holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Palo Alto Investors LP's ORKA position evolved
Palo Alto Investors LP first disclosed a stake in ORKA in Q3 2025 at 59,985 shares (US$791K). The position peaked in Q2 2026 at 33,546 shares, worth US$3.2M. Across 5 filings, Palo Alto Investors LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 25,563 shares valued at US$2.1M — a reduction of -7,983 shares quarter over quarter.. Notable position changes include a 44% trim in Q2 2026 (shares fell 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 59.98K | $791.31K | New |
| Q4 2025 | 59.98K | $1.82M | Hold |
| Q1 2026 | 59.98K | $2.94M | Hold |
| Q2 2026 | 33.55K | $3.19M | Reduce |
| Q3 2026 | 25.56K | $2.13M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ORKA and 13F data
ORKA (ORUKA THERAPEUTICS INC) is a Health Care company. 74 other funds we track also report a position in ORKA — the largest reported positions include Venrock Adviser, LLC (US$345.5M), Fairmount Funds Management LLC (US$308.6M), RTW INVESTMENTS, LP (US$261.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ORKA
- Venrock Adviser, LLC 4.15M sh · $345.52M · Q3 2026
- Fairmount Funds Management LLC 3.71M sh · $308.61M · Q3 2026
- RTW INVESTMENTS, LP 3.14M sh · $261.45M · Q3 2026
- Paradigm Biocapital Advisors LP 2.49M sh · $207.68M · Q3 2026
- Bellevue Group AG 1.64M sh · $136.68M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 1.55M sh · $129.48M · Q3 2026
- PERCEPTIVE ADVISORS LLC 1.07M sh · $89.32M · Q3 2026
- Deep Track Capital, LP 1.07M sh · $89.10M · Q3 2026
- Remedium Capital Partners, LLC 954.15K sh · $79.47M · Q3 2026
- Avidity Partners Management LP 785.42K sh · $65.42M · Q3 2026
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 723.92K sh · $60.30M · Q3 2026
- Affinity Asset Advisors, LLC 600.00K sh · $49.97M · Q3 2026
More on Palo Alto Investors LP
FAQ
How long has Palo Alto Investors LP held ORKA?
Palo Alto Investors LP has disclosed ORKA holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Palo Alto Investors LP's current position in ORKA?
As of Q3 2026, Palo Alto Investors LP holds 25.56K shares of ORKA (ORUKA THERAPEUTICS INC), valued at $2.13M, representing 0.32% of its reported portfolio and ranking #38.
Has Palo Alto Investors LP been buying or selling ORKA?
In the latest 13F filing (Q3 2026), Palo Alto Investors LP reduced its position in ORKA. The position peaked in Q2 2026 at 33.55K shares.
Which other funds hold ORKA?
Other major institutional holders of ORKA include Venrock Adviser, LLC, Fairmount Funds Management LLC, RTW INVESTMENTS, LP, among 74 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.